Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-03
2011-05-03
Spivack, Phyllis G (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07935717
ABSTRACT:
The invention is directed to a method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia by administration of a1-methylnicotinamide salt.
REFERENCES:
patent: 5260305 (1993-11-01), Dennick
patent: 6090830 (2000-07-01), Myers et al.
patent: 6129930 (2000-10-01), Bova
patent: 6406715 (2002-06-01), Cefali
patent: 6469035 (2002-10-01), Cefali
patent: 6676967 (2004-01-01), Cefali et al.
patent: 6746691 (2004-06-01), Cefali
patent: 6818229 (2004-11-01), Cefali et al.
patent: 7011848 (2006-03-01), Bova
patent: 7153870 (2006-12-01), Mathias
patent: 2001/0014338 (2001-08-01), Cefali
patent: 2003/0157153 (2003-08-01), Cefali
patent: 2003/0161880 (2003-08-01), Cefali
patent: 2004/0132737 (2004-07-01), Cormier et al.
patent: 2005/0130990 (2005-06-01), Cormier et al.
patent: 2005/0255158 (2005-11-01), Bova
patent: 2006/0263428 (2006-11-01), Cefali
patent: 2007/0249622 (2007-10-01), Cormier et al.
patent: 2008/0221085 (2008-09-01), Cormier et al.
patent: 2008/0221172 (2008-09-01), Marcinek et al.
patent: WO 99/06046 (1999-02-01), None
patent: WO/00/40559 (2000-07-01), None
patent: WO-00/40559 (2000-07-01), None
patent: WO-2005/067927 (2005-07-01), None
patent: WO/2006/052569 (2006-05-01), None
Fung et al. (CMAJ, vol. 167, No. 11, pp. 1261-1266; 2002).
Oettgen et al. (Cancer Research, vol. 20, pp. 1597-1601; 1960).
Patani et al. (Chem. Rev., vol. 96, No. 8, pp. 3147-3176; 1996).
Wagner et al. (Diabetes Care, vol. 22, pp. 812-817; 1999).
“Trigonella foenum-graecum”, XP002445860.
Filetti, S. et al, “Insulin Receptor Down-Regulation: Prevention at a Post-Receptor Site,”Endocrinology, vol. 108(6):2409-2411 (1981).
Fischer, L.J. et al, “Characteristics of Nicotinamide andN1-Methylnicotinamide Protection from Alloxan Diabetes in Mice,”Toxicology and Applied Pharmacology, vol. 70:148-155 (1983).
Fukushima, Tetsuhito et al, “Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease,”Exp. Toxic Pathol., vol. 53:469-473 (2002).
Fukushima, T. et al, “Radical Formation Site of Cerebral Complex I and Parkinson's Disease,”Journal of Neuroscience Research, vol. 42:385-390 (1995).
Gebicki, Jerzy et al, “1-Methylnicotinamide: A Potent Anti-Inflammatory Agent of Vitamin Origin,”Polish Journal of Pharmacology, vol. 55:109-112 (2003).
Lea, Michael A. et al, “Effects of Nicotinamide and Structural Analogs on DNA Synthesis and Cellular Replication of Rat Hepatoma Cells,”Cancer Biochem. Biophys., vol. 7:195-202 (1984).
Taguchi, Hiroshi, “Vitamins and apoptosis—Induction of apoptosis in human cancer cells by nicotinic acid-related compounds,”Nippon Rinsho., vol. 57(10):2319-2324 (1999).
International Search Report for Application No. PCT/EP2005/050057, dated Sep. 30, 2005.
Carlson, L. A. et al, Atherosclerosis, 1972, 16:359-368.
Filetti, S., et al, Endocrinology, 108(6), 2409-2411 (1981).
Fischer, L. J., et al, Toxicology and Applied Pharmacology 70, 148-155 (1983).
Fukushima, T. et al, Exp Toxic Pathol 2002; 53: 469-473.
Fukushima, T. et al, Journal of Neuroscience Research 42:385-390 (1995).
Gebicki, et al, Pol. J. Pharmacol., 2003, 55, 109-112.
Lea, et al, Cancer Biochem Biophys.,1984, vol. 7, 195-202.
Shibata, et al, Am. J. Clin. Nutr., 1989; 50:114-119.
Taguchi, H., et al., J. Active Oxygens and Free Radicals, v. 14 (1999), pp. 23-28.
Harper's Biochemistry, Twenty-second Edition, R.K. Murray, et al,. eds., Appleton & Lange, Norwalk, CT, 1990, pp. 549-551.
DE 840 698, Partial English translation of p. 1, lines 1-24.
Bartuś, M., et al., “1-Methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats,”Pharmacol Rep. 60:127-138, Institute of Pharamacology Polish Academy of Sciences (Jan.-Feb. 2008).
Bodor, E.T., and Offermanns, S., “Nicotinic acid: an old drug with a promising future,”Br. J. Pharmacol. 153:S68-S75, Nature Publishing Group (Mar. 2008).
Carlson, L.A., et al., “Nicotinic acid: the broad-spectrum lipid drug. A 50thanniversary review,”J. Intern. Med. 258:94-114, Blackwell Publishing Ltd. (Aug. 2005).
Dalton, C., et al., “Relationship of Nicotinamide and Nicotinic Acid to Hypolipidemia,”Biochem. Pharma. 19:2609-2619, Pergamon Press (Jul. 1970).
Jaconello, P., Mattiussi, A., Blais, D., “Niacin versus niacinamide,”Can. Med. Assoc. J. 147:990, CMA (Oct. 1992).
Pike, Nicholas B., “Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid,”The J. of Clin. Invest., 115:3400-3403, American Society for Clinical Investigation (Dec. 2005).
Walter, Anthony A.J., “Megavitamin and megamineral therapy in childhood,”Can. Med. Assoc. J. 146:2140, CMA (Jun. 1992).
Wise, A., et al., “Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid,”J. Biol. Chem. 278(11):9868-9874, The American Society for Biochemistry and Molecular Biology, Inc. (Mar. 2003).
Chlopicki Stefan
Gebicki Jerzy
Blakely, III Nelson C
Pharmena Spolka Akcyjna (Pharmena S.A.)
Spivack Phyllis G
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Method for treating hypertriglyceridemia, dyslipidemia and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating hypertriglyceridemia, dyslipidemia and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating hypertriglyceridemia, dyslipidemia and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648491